Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

Overview of attention for article published in New England Journal of Medicine, August 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 12 news outlets
blogs: 2 blogs
twitter: 266 X users
patent: 1 patent
facebook: 12 Facebook pages
wikipedia: 3 Wikipedia pages

googleplus: 3 Google+ users
reddit: 3 Redditors
f1000: 1 research highlight platform
guideline: 5 clinical guideline sources
bluesky: 2 Bluesky users

Readers on

mendeley: 571 Mendeley
citeulike: 2 CiteULike

So far, Altmetric has seen 14 news stories from 12 outlets.

CHMP backs first CETP inhibitor after two decades of failure

European Biotechnology, 29 Jul 2026

Why it matters: A new class of cholesterol drug is finally close to reaching the European market.

VIDEO: Anacetrapib doubles HDL, but patients gain from its modest LDL cut

Pediatric News , 09 Jun 2026

Daily treatment with 100 mg of anacetrapib on top of intensive therapy with atorvastatin led to a 9% relative risk reduction in…

Women in Cardiovascular Research; Past, Present and Future

Doc Wire News, 09 Mar 2023

Enrollment of women in cardiovascular clinical trials has traditionally been much lower than men.

Traditional Mongolian Medicine Baolier Capsule

Health Reporter, 13 Feb 2023

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 10 additional news stories.